Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

13 trials match this view; 30 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 1,081 across 13 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

202011
202122
202211
202311
202433
202522
202633

Current indexed registry status

Recruiting44
Active, not recruiting44
Completed22
Unknown status22
Not yet recruiting11

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Countries with reported trial locations

Canada4141

Sponsors recorded in this index

Matching trial records

13 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial

NCT07296094

Alcohol Use Disorder
Brigham and Women's Hospital

PHASE2

Not yet recruiting

Registry updated 2026-09-24

36

ESTIMATED

2026-11-15
2029-12-01
2030-02
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder

NCT06349083

Alcohol Use Disorder
NYU Langone Health

PHASE2

Recruiting

Registry updated 2026-09-02

200

ESTIMATED

2026-09-01
2030-05
2030-05
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

NCT07638553

Alcohol Use Disorder · Depressive Sympotoms · Psilocybin
Centre Hospitalier Universitaire de Nīmes

PHASE3

Recruiting

Registry updated 2026-07-01

172

ESTIMATED

2026-06-30
2030-06
2030-06
The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.

NCT05416229

Alcohol Use Disorder
Anders Fink-Jensen, MD, DMSci

PHASE2

Completed

Registry updated 2026-03-24

60

ACTUAL

2023-09-01
2025-12-22
2025-12-22
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759

Major Depressive Disorder · Alcohol Use Disorder
Johns Hopkins University

PHASE2

Active, not recruiting

Registry updated 2026-03-13

90

ESTIMATED

2021-04-14
2026-03-02
2027-03-30
Psilocybin vs Ketamine for Alcohol Use Disorder

NCT06405607

Alcohol Use Disorder · Alcohol Dependence · Alcohol Abuse
University of Iowa

PHASE2

Recruiting

Registry updated 2025-11-28

80

ESTIMATED

2025-06-12
2028-04
2028-04
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

NCT05421065

Alcohol Use Disorder
Peggy C Nopoulos

PHASE2

Active, not recruiting

Registry updated 2025-11-17

20

ESTIMATED

2024-02-02
2025-08-30
2026-09
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

NCT07189988

Alcohol Use Disorder
Healing Advocacy Fund

Phase not reported

Active, not recruiting

Registry updated 2025-09-24

20

ACTUAL

2025-03-05
2026-06-10
2026-08-05
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

NCT05646303

Alcohol Use Disorder
Clairvoyant Therapeutics

PHASE2

Unknown status

Registry updated 2024-08-15

128

ESTIMATED

2022-05-02
2024-08-31
2024-12-31
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243

Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
University of Sydney

PHASE2

Unknown status

Registry updated 2024-06-10

90

ESTIMATED

2024-09
2025-07
2025-12
Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial

NCT05995769

Alcohol Use Disorder · Alcoholism
University of Calgary

PHASE2

Recruiting

Registry updated 2024-05-07

128

ESTIMATED

2024-03-20
2027-10-01
2027-10-01
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder

NCT04141501

Alcohol Use Disorder
University of Zurich

PHASE2

Completed

Registry updated 2023-09-21

37

ACTUAL

2020-06-08
2023-03-14
2023-09-14
Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT04410913

Alcohol Use Disorder
Keith Heinzerling

PHASE2

Active, not recruiting

Registry updated 2023-01-17

20

ACTUAL

2021-02-18
2023-02
2023-02

Reported research facilities

Brigham and Women's HospitalBoston, Massachusetts, United States
NYU Langone HealthNew York, New York, United States
Centre Hospitalier de la Côte BasqueBayonne, France
CHU BesançonBesançon, France
CHU de BordeauxBordeaux, France
CHU BrestBrest, France
CH Le VinatierBron, France
CHU de NantesNantes, France
CHU de NîmesNîmes, France
CHU Saint-EtienneSaint-Priest, France
Psychiatric Center Copenhagen, Frederiksberg HospitalFrederiksberg, Denmark
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States
University of Iowa Health CareIowa City, Iowa, United States
University of IowaIowa City, Iowa, United States
Innertrek Patient Service CenterPortland, Oregon, United States
Sabi MindCalgary, Alberta, Canada
Okanagan Clinical TrialsKelowna, British Columbia, Canada
Centre for Neurology StudiesSurrey, British Columbia, Canada
University of British Columbia, Department of Psychiatry, BRAIN LabVancouver, British Columbia, Canada
Centricity ResearchHalifax, Nova Scotia, Canada
MacAnxiety Research CentreHamilton, Ontario, Canada
Department of Psychiatry, Queen's UniversityKingston, Ontario, Canada
Centre for Addiction and Mental HealthToronto, Ontario, Canada
Research Center Oxidi Oy / Addiktum OyHelsinki, Finland
A-KlinikkaKouvola, Finland
Mentacare OyOulu, Finland
Addiktum OyTurku, Finland
University of CalgaryCalgary, Alberta, Canada
Psychiatrische Universitätsklinik ZürichZurich, Switzerland
Pacific Treatment & Research in PsychedelicsSanta Monica, California, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.